Quantcast

Latest BPH Stories

2009-05-14 11:00:00

Initial results from preclinical and Phase 1 safety studies, and plans for Phase 2 studies for menopausal symptoms and benign prostatic hyperplasia (BPH) are to be presented CINCINNATI, May 14 /PRNewswire/ -- Ausio Pharmaceuticals, LLC, a biotechnology development company focused on medicines for an aging global population, will lead off the Bio(R) Business Forum in a presentation on May 19, 2009 at 9:00 AM in Atlanta, Georgia. Ausio has developed AUS-131, a pharmaceutical formulation of the...

2009-05-08 06:50:00

- Significant peak urine flow (Qmax) improvements within 2-6 hours of the first dose, according to published data - CORONA, Calif., May 8 /PRNewswire-FirstCall/ -- RAPAFLO(TM) (silodosin), a new, uniquely selective alpha blocker for the treatment of the signs and symptoms of BPH, produces rapid improvements of both irritative and obstructive urinary symptoms that were sustained for 12 weeks, according to data published in the June issue of The Journal of Urology. RAPAFLO(TM) was...

2009-05-06 06:00:00

All amounts are in U.S. dollars QUEBEC CITY, May 6 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: AEZS, TSX: AEZ) ("the Company"), a global biopharmaceutical company focused on endocrinology and oncology, today reported financial and operating results as at and for the three months ended March 31, 2009. First Quarter 2009 Highlight Signing of partnership with sanofi-aventis for cetrorelix in benign prostatic hyperplasia ("BPH") for the U.S. market: - Initial $30...

2009-04-28 15:05:00

- Uniquely Selective Agent Offers Significant Improvement - CHICAGO, April 28 /PRNewswire-FirstCall/ -- Data to be presented at the American Urological Association's (AUA) Annual Conference show that RAPAFLO(TM) (silodosin) produces rapid and sustained improvements of both irritative and obstructive urinary symptoms associated with BPH, with statistically significant symptom relief within three to four days of starting treatment. RAPAFLO(TM) is a new, uniquely selective alpha blocker for...

2009-04-28 10:30:00

-- Data Presented at American Urological Association Annual Meeting -- SEATTLE and CHICAGO, April 28 /PRNewswire-FirstCall/ -- Researchers from Dendreon Corporation (Nasdaq: DNDN) today presented preclinical data demonstrating the potential of D-3263, Dendreon's orally bioavailable small molecule, which targets TRPM8 (a transmembrane cation channel protein), to treat benign prostatic hyperplasia (BPH). D-3263 demonstrated the ability to reduce BPH alone and in combination with finasteride,...

2009-04-27 07:00:00

DENVER, April 27 /PRNewswire-USNewswire/ -- Phase II data presented at the annual meeting of the American Urology Association (AUA) indicate that men suffering from an enlarged prostate may benefit from BOTOX(R) injections. The two-stage, multi-center, double-blind, randomized study showed that two different dose levels of Botulinium Neurotoxin Type A (BOTOX) injected into the prostate was both safe and efficacious for the management of benign prostatic hyperplasia (BPH), a common...

2009-04-22 23:01:00

SANTA CLARA, Calif., April 23 /PRNewswire/ -- Lumenis Inc., a subsidiary of Lumenis Ltd., a global developer, manufacturer and seller of laser, light-based and radiofrequency devices for surgical, aesthetic, and ophthalmic applications, announced today at the American Urological Association's (AUA) annual show the introduction of a Holmium Laser Enucleation of the Prostate (HoLEP) training simulator and the PolyScope Disposable Ureteroscope(1), a new flexible scope with enhanced vision and...

2009-04-07 06:30:00

-- New product, now available in pharmacies, will provide rapid symptom relief for number one reason men visit a urologist -- CORONA, Calif., April 7 /PRNewswire-FirstCall/ --Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today that RAPAFLO(TM) (silodosin), the company's new, uniquely selective alpha blocker for the treatment of the signs and symptoms of benign prostatic hyperplasia (BPH), is available for patients by prescription. Watson...

2009-03-31 11:00:00

Supporting men's health awareness by exploring solutions to the most common health problem for men over the age of 60 ROSEMEAD, Calif., March 31 /PRNewswire/ -- The causes and treatments of enlarged prostate will be the focus of a free community seminar on April 2, 2009 at 6:30pm at the Doubletree Hotel in Rosemead. Also known as benign prostatic hyperplasia (BPH), this non-cancerous enlargement of the prostate affects more than half of all men over the age of 60 and more than 26 million men...

2009-03-31 09:00:00

Supporting men's health awareness by exploring solutions to the most common health problem for men over the age of 60 NEENAH, Wis., March 31 /PRNewswire/ -- The causes and treatments of enlarged prostate will be the focus of a free community seminar on April 2, 2009 at 6:30pm at the Theda Clark Medical Center in Neenah. Also known as benign prostatic hyperplasia (BPH), this non-cancerous enlargement of the prostate affects more than half of all men over the age of 60 and more than 26 million...


Word of the Day
pungle
  • To take pains; labor assiduously with little progress.
This word comes from the Spanish 'pongale,' put it.
Related